Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012

Bibliography

• De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and gamma-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006304
   PubMed Web of Science ®Google Scholar
• Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698-712
   PubMed Web of Science ®Google Scholar
• Kreft AF, Martone R, Porte A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem 2009;52:6169-88
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Panza F, Frisardi V, et al. Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 2011;20:325-41
   PubMed Web of Science ®Google Scholar
• Sambamurti K, Greig NH, Utsuki T, et al. Targets for AD treatment: conflicting messages from gamma-secretase inhibitors. J Neurochem 2011;117:359-74
   PubMed Web of Science ®Google Scholar
• Schor NF. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 2011;69:237-9
   PubMed Web of Science ®Google Scholar
• Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012;69:1430-40
   PubMed Web of Science ®Google Scholar
• Crump CJ, Castro SV, Wang F, et al. BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry 2012;51:7209-11
   PubMed Web of Science ®Google Scholar
• Chavez-Gutierrez L, Bammens L, Benilova I, et al. The mechanism of gamma-secretase dysfunction in familial Alzheimer disease. EMBO J 2012;31:2261-74
   PubMed Web of Science ®Google Scholar
• McKee TD, Loureiro RM, Dumin JA, et al. An improved cell-based method for determining the gamma-secretase enzyme activity against both Notch and APP substrates. J Neurosci Methods 2013;213:14-21
   PubMed Web of Science ®Google Scholar
• Albright CF, Dockens RC, Meredith JE Jr, et al. Pharmacodynamics of selective inhibition of gamma-secretase by avagacestat. J Pharmacol Exp Ther 2013;344:686-95
   PubMed Web of Science ®Google Scholar
• Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-16
   PubMed Web of Science ®Google Scholar
• Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta42 in vivo. J Clin Invest 2003;112:440-9
   PubMed Web of Science ®Google Scholar
• Weggen S, Eriksen JL, Sagi SA, et al. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003;278:30748-54
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Hayashi I, Tominari Y, et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta42 generation. J Biol Chem 2003;278:18664-70
   PubMed Web of Science ®Google Scholar
• Pettersson M, Kauffman GW, am Ende CW, et al. Novel gamma-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Pat 2011;21:205-26
   PubMed Web of Science ®Google Scholar
• Oehlrich D, Berthelot DJ, Gijsen HJ. gamma-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem 2011;54:669-98
   PubMed Web of Science ®Google Scholar
• Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. Curr Top Med Chem 2008;8:47-53
   PubMed Web of Science ®Google Scholar
• Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-64
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Del Giudice E, Colavito D, et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 2007;323:822-30
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Frigerio E, Breda M, et al. Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. Alzheimer Dis Assoc Disord 2012; doi.org/10.1097/WAD.0b013e3182622ace
   Web of Science ®Google Scholar
• Page RM, Baumann K, Tomioka M, et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 2008;283:677-83
   PubMed Web of Science ®Google Scholar
• Ohki Y, Higo T, Uemura K, et al. Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J 2011;30:4815-24
   PubMed Web of Science ®Google Scholar
• Crump CJ, Fish BA, Castro SV, et al. Piperidine acetic acid based gamma-secretase modulators directly bind to presenilin-1. ACS Chem Neurosci 2011;2:705-10
   PubMed Web of Science ®Google Scholar
• Kounnas MZ, Danks AM, Cheng S, et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010;67:769-80
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Ishibashi A, Hagiwara H, et al. E2012: A novel gamma-secretase modulator - pharmacology. Alzheimers Dement 2010;6(Suppl):S242
   Google Scholar
• Portelius E, Van Broeck B, Andreasson U, et al. Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 2010;21:1005-12
   PubMed Web of Science ®Google Scholar
• Findeis MA, Schroeder F, McKee TD, et al. Discovery of a novel pharmacological and structural class of gamma-secretase modulators derived from the extract of Actaea racemosa. ACS Chem Neurosci 2012;3:941-51
   PubMed Web of Science ®Google Scholar
• Crump CJ, Johnson DS, Li YM. Development and mechanism of gamma-secretase modulators for Alzheimer's disease. Biochemistry 2013;52:3197-216
   PubMed Web of Science ®Google Scholar
• cLogP (version 4.3). BioByte Corp
   Google Scholar
• Ertl P, Rohde B, Selzer P. Fast Calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000;43:3714-17
   PubMed Web of Science ®Google Scholar
• Hattori K, Wakabayashi H, Tamaki K. Predicting key example compounds in competitors' patent applications using structural information alone. J Chem Inf Model 2008;48:135-42
   PubMed Web of Science ®Google Scholar
• Hall A, Elliott RL, Giblin GM, et al. Piperidine-derived gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:1306-11
   PubMed Web of Science ®Google Scholar
• Hawkins J, Harrison DC, Ahmed S, et al. Dynamics of Abeta42 reduction in plasma, CSF and brain of rats treated with the gamma-secretase modulator. GSM-10h. Neurodegener Dis 2011;8:455-64
   PubMed Web of Science ®Google Scholar
• Li T, Huang Y, Jin S, et al. gamma-Secretase modulators do not induce Abeta-rebound and accumulation of beta-C-terminal fragment. J Neurochem 2012;121:277-86
   PubMed Web of Science ®Google Scholar
• Hussain I, Harrison DC, Hawkins J, et al. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to gamma-secretase modulation and Abeta42 lowering by GSM-10h. Neurodegener Dis 2011;8:15-24
   PubMed Web of Science ®Google Scholar
• Mitani Y, Yarimizu J, Saita K, et al. Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 2012;32:2037-50
   PubMed Web of Science ®Google Scholar
• Mitani Y, Yarimizu J, Akashiba H, et al. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Abeta42 without affecting other Abeta pools. J Neurochem 2013;125:465-72
   PubMed Web of Science ®Google Scholar
• Am Ende CW, Fish BA, Johnson DS, et al. Pfizer, Inc., USA. Aminocyclohexanes and aminotetrahydropyrans as gamma-secretase modulators and their preparation and use for the treatment of neurological and psychiatric diseases. WO2011092611A1; 2011
   Google Scholar
• Yamasaki S, Honjo E, Samizu K, et al. Astellas Pharma, Inc., Japan. Preparation of cycloalkane compounds as gamma-secretase modulators. WO2012046771A1; 2012
   Google Scholar
• Shapiro G, Chesworth R, EnVivo Pharmaceuticals, Inc., USA. Preparation of tetrasubstituted benzenes as gamma-secretase modulators for treating Alzheimer's Disease. W02009086277A1; 2009
   Google Scholar
• Rogers K, Felsenstein KM, Hrdlicka L, et al. Modulation of gamma-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener 2012;7:61
   PubMed Web of Science ®Google Scholar
• Ho C, Schering Corp., USA. Preparation of biphenyl derivatives as gamma-secretase modulators. WO2009052341A1; 2009
   Google Scholar
• Van Broeck B, Chen JM, Treton Y, et al. Chronic treatment with a novel gamma-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br J Pharmacol 2011;163:375-89
   PubMed Web of Science ®Google Scholar
• Peng H, Cuervo JH, Ishchenko A, et al. Biogen Idee Ma, Inc., USA. Preparation of carboxylic acid-containing compounds and derivatives thereof useful in treating Alzheimer's disease. WO2010138901A1; 2010
   Google Scholar
• Xin Z, Peng H, Zhang A, et al. Discovery of 4-aminomethylphenylacetic acids as gamma-secretase modulators via a scaffold design approach. Bioorg Med Chem Lett 2011;21:7277-80
   PubMed Web of Science ®Google Scholar
• Peng H, Talreja T, Xin Z, et al. Discovery of BIIB042, a potent, selective, and orally bioavailable gamma-secretase modulator. ACS Med Chem Lett 2011;2:786-91
   PubMed Web of Science ®Google Scholar
• Bulic B, Ness J, Hahn S, et al. Chemical biology, molecular mechanism and clinical perspective of gamma-secretase modulators in Alzheimer's disease. Current Neuropharmacology 2011;9:598-622
   PubMed Web of Science ®Google Scholar
• Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem 2008;8:54-61
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov [Last accessed 15 May 2013]
   Google Scholar
• Zhu Z, Greenlee W, Sun Z-Y, et al. Schering Corp., USA. Preparation of substituted alkenyloxadiazole derivatives and analogs as gamma-secretase modulators. WO2008137139A1; 2008
   Google Scholar
• Sun ZY, Asberom T, Bara T, et al. Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious gamma-secretase modulators in vivo. J Med Chem 2012;55:489-502
   PubMed Web of Science ®Google Scholar
• Zhu Z, Greenlee W, Huang X, et al. Schering Corp., USA. Preparation of phenylhexahydroimidazopyridine derivatives and analogs as gamma-secretase modulators. WO2008153793A2; 2008
   Google Scholar
• Huang X, Zhou W, Liu X, et al. Synthesis and SAR studies of fused oxadiazines as gamma-secretase modulators for treatment of Alzheimer's disease. ACS Med Chem Lett 2012;3:931-5
   PubMed Web of Science ®Google Scholar
• Zhu Z, Greenlee W, Li H, et al. Schering Corp., USA. Heterocyclic compounds as gamma-secretase modulators and their preparation and use in the treatment of CNS diseases. WO2010056722A1; 2010
   Google Scholar
• Li H, Qin J, Dhondi P, et al. The discovery of fused oxadiazepines as gamma-secretase modulators for treatment of Alzheimer's disease. Bioorg Med Chem Lett 2013;23:466-71
   PubMed Web of Science ®Google Scholar
• Huang X, Zhu Z, Greenlee WJ, et al. Schering Corp., USA. Heterocyclic fused pyridines as gamma secretase modulators and their preparation and use in the treatment of Alzhemier's diseases. WO2010147973A1; 2010
   Google Scholar
• Huang X, Zhu Z, Greenlee WJ, et al. Schering Corp., USA. Heterocyclic fused pyridines as gamma secretase modulators and their preparation, and use in the treatment of Alzheimer's disease. WO2010147975A1; 2010
   Google Scholar
• Zhu Z, Huang X, Palani A, et al. Schering Corp., USA. Gamma-Secretase modulators. WO2010147969A2; 2010
   Google Scholar
• Gijsen H, Bischoff F, Zhuang W, et al. Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Substituted benzoxazole, benzimidazole, oxazolopyridine and Imidazopyridine derivatives as gamma-secretase modulators and their preparation and use for the treatment of diseases. WO2010094647A1; 2010
   Google Scholar
• Bischoff FP, Gijsen HJM, Pieters SMA, Minne GB; Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Preparation of substituted indazole and aza-indazole derivatives as gamma-secretase modulators. WO2010145883A1; 2010
   Google Scholar
• Bischoff F, Berthelot D, De Cleyn M, et al. Design and synthesis of a novel series of bicyclic heterocycles as potent gamma-secretase modulators. J Med Chem 2012;55:9089-106
   PubMed Web of Science ®Google Scholar
• Van Brandt SFA, De Cleyn MAJ, Gijsen HJM, et al. Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Triazole derivatives as gamma-secretase modulators and their preparation and use for the treatment of diseases. WO2011086099A1; 2011
   Google Scholar
• Keserue GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8:203-12
   PubMed Web of Science ®Google Scholar
• Gijsen HJM, Mercken M. Gamma-secretase modulators: can we combine potency with safety? Int J Alzheimers Dis 2012;2012:295207
   PubMedGoogle Scholar
• De Cleyn MAJ, Van Brandt SFA, Gijsen HJM, et al. Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Triazole derivatives as gamma-secretase modulators and their preparation and use for the treatment of diseases. WO2011086098A1; 2011
   Google Scholar
• Baumann K, Goetschi E, Green L, et al. F. Hoffmann-La Roche AG, Switz. Preparation of phenyltriazolopyridinylimidazolylphenylamine derivatives and analogs for use as gamma-secretase modulators. WO2011092272A1; 2011
   Google Scholar
• Boy KM, Guernon JM, Macor JE, et al. Bristol-Myers Squibb Co., USA. Preparation of fused pyrimidine compounds as modulators of beta-amyloid production. US20120028994; 2012
   Google Scholar
• Boy KM, Guernon JM, Macor JE, et al. Bristol-Myers Squibb Co., USA. Preparation of macrocyclic compounds fused to benzene and pyrimidine rings for the reduction of beta-amyloid production. WO2012009309A1; 2012
   Google Scholar
• Boy KM, Guernon JM, Macor JE, et al. Bristol-Myers Squibb Co., USA. Preparation of bicyclic pyrimidine compounds for the reduction of beta-amyioid production. WO2012103297A1; 2012
   Google Scholar
• Lo-Alfredsson Y, Paulsen K, Rakos L, et al. AstraZeneca AB, Swed. Preparation of pyridooxazepine derivatives for use as gamma-secretase modulators and treatment of alpha beta related pathologies, such as Alzheimer's disease. WO2010132015A1; 2010
   Google Scholar
• Macsari I, Paulsen K, Rakos L, et al. AstraZeneca AB, Swed. Preparation of pyrido[3,2-f][l,4]oxazepine compounds and their use for treatment of Abeta-related diseases. WO2012064269A1; 2012
   Google Scholar
• Kimura T, Doi E, Doko T, et al. Eisai R&D Management Co., Ltd., Japan. Preparation of aryl imidazole compounds and their use as beta amyloid production inhibitors. WO2010098488A1; 2010
   Google Scholar
• Kitazawa N, Shinmyo D, Ito K, et al. Eisai R&D Management Co., Ltd., Japan. Nitrogen-containing fused heterocyclic compounds as beta-amyloid production inhibitors and their preparation and use for the treatment diseases caused by Abeta. WO2010098487A1; 2010
   Google Scholar
• Hasegawa D, Kitazawa N; Eisai R&D Management Co., Ltd., Japan. Preparation of 2-(imidazol-1-yl)pyrazine derivatives as inhibitors of protein amyloid-beta (Abeta). WO2010098495A1; 2010
   Google Scholar
• Wu T, Gijsen HJM, Rombouts FJR, et al. Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Preparation of substituted phenyltriazole derivatives and analogs for use as gamma secretase modulators associated with beta-amyloid. WO2011006903A1; 2011
   Google Scholar
• Koike T, Hoashi Y, Tomata Y; Takeda Pharmaceutical Co., Ltd, Japan. Preparation of Heterocyclic compounds as inhibitors for production of amyloid beta protein. WO2011007756Al; 2011
   Google Scholar
• Koike T, Nakamura M, Tomata Y, et al. Takeda Pharmaceutical Co., Ltd, Japan. Preparation of fused triazoles for the treatment or prophylaxis of mild cognitive impairment. WO2012029991A1; 2012
   Google Scholar
• Iwama S, Ikeda T, Kobayashi T; Dainippon Sumitomo Pharma Co., Ltd., Japan. Preparation of 4-(4-pyridinyOphenyl-substituted fused 1,2,4-triazole derivatives as inhibitors of beta-amyloid production. WO2012057300A1; 2012
   Google Scholar
• Kounnas MZ, Ackerman EJ, Stauderman KA, et al. NeuroGenetic Pharmaceuticals, Inc., USA. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor. WO2011057214A2; 2011
   Google Scholar
• Wagner SL, Cheng S, Mobley WC, Tanzi RE; University of California, USA. Preparation of heterocyclic compounds and therapeutic use thereof as modulators of various amyloid beta peptide alloforms. WO2011163636A2; 2011
   Google Scholar
• Iwama S, Nakagawa H, Kato Y, Dainippon Sumitomo Pharma Co., Ltd., Japan. Oxadiazole derivative as therapeutic agent for beta-amyioid-associated neuropsychiatrie disorders. WO2011001931A1; 2011
   Google Scholar
• Am Ende CW, Johnson DS, O'Donnell CJ, et al. Pfizer, Inc., USA. Preparation of heteroaryl imidazoles and heteroaryi triazoles as gamma-secretase modulators. WO2O11048525A1; 2011
   Google Scholar
• Pettersson M, Johnson DS, Subramanyam C, et al. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active gamma-secretase modulators. Bioorg Med Chem Lett 2012;22:2906-11
   PubMed Web of Science ®Google Scholar
• Am Ende CW, Fish BA, Green ME, et al. Pfizer, Inc., USA. Preparation of pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma-secretase modulators. WO2012131539A1; 2012
   Google Scholar
• Iwama S, Kato Y, Kobayashi T, Fusano A, Dainippon Sumitomo Pharma Co., Ltd., Japan. Preparation of 4-(1H-imidazol-1-y)benzamide and (1H-imidazol-1-y)pyridinecarboxamide derivatives as beta amyloid 42 production inhibitors. WO2011059048Al; 2011
   Google Scholar
• Koike T, Raker J; Takeda Pharmaceutical Co., Ltd, Japan. Preparation of 1-[4-(1H-imidazol-1-yl)phenyl]-1, and -pyrrolidine derivatives as inhibitors of amyloid-beta production. WO2011016559A1; 2011
   Google Scholar
• Terauchi J, Koike T, Honda E; Takeda Pharmaceutical Co., Ltd, Japan. Preparation of piperazines and related compounds for inhibiting amyloid-beta production. WO2011002067A1; 2011
   Google Scholar
• Kato I, Kano K; Shionogi & Co., Ltd., Japan. Preparation of lactam or benzenesulfonamide compounds as inhibitors for production of amyloid beta protein. WO2011007819A1; 2011
   Google Scholar
• Bischoff FP, Velter Al, Van Brandt SFA, Berthelot DJ-C, Janssen Pharmaceuticals, inc., USA. Preparation of triazolylpiperazine derivatives and analogs for use as gamma-secretase modulators. WO2012126984A1; 2012
   Google Scholar
• Baumann K, Green L, Limberg AF; Hoffmann-La Roche AG, Switz. Preparation of bridged piperidine derivatives for use as amyloid beta modulators. WO2012116965A1; 2012
   Google Scholar
• Kobayashi N, Nishitomi A, Fuchino K; Shionogi and Co., Ltd., Japan. Preparation of indole-amide compounds for inhibiting amyloid-beta production. JP2012107001A; 2012
   Google Scholar
• Bronk BS, Austin WF, Creaser SP, et al. Satori Pharmaceuticals, Inc., USA. Preparation of cholestane derivatives useful for treating neurodegenerative disorders. WO2011109657A1; 2011
   Google Scholar
• Fuller NO, Hubbs JL, Austin WF, et al. Initial optimization of a new series of gamma-secretase modulators derived from a triterpene glycoside. ACS Med Chem Lett 2012;3:908-13
   PubMed Web of Science ®Google Scholar
• Hubbs JL, Fuller NO, Austin WF, et al. Optimization of a natural product-based class of gamma-secretase modulators. J Med Chem 2012;55:9270-82
   PubMed Web of Science ®Google Scholar
• Tate B, McKee TD, Loureiro RM, et al. Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis 2012;2012:210756
   PubMedGoogle Scholar
• Available from: http://www.fiercebiotech.com/story/satori-pharmaceuticals-shuts-down-after-failure-alzheimers-drug/2013-05-30
   Google Scholar
• Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 2009;52:6752-6
   PubMed Web of Science ®Google Scholar
• Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 2010;1:425-49
   Web of Science ®Google Scholar
• Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18:4872-5
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Research and Manufacturers of America, Medicines in development for Alzheimer's disease. 2012. Available from: http://www.phrma.org/sites/default/files/pdf/alzheimers2012.pdf
   Google Scholar
• Li X, Dang S, Yan C, et al. Structure of a presenilin family intramembrane aspartate protease. Nature 2013;493:56-61
   PubMed Web of Science ®Google Scholar
• Pozdnyakov N, Murrey HE, Crump CJ, et al. gamma-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem 2013;288:9710-20
   PubMed Web of Science ®Google Scholar